Pay in 4 interest-free payments of $6.66 Learn more
Ships within 48 hours Β· Estimated delivery Aug 19 - Aug 24
The proportion of patients achieving HbA1c of less than 7 % without severe or confirmed episodes of hypoglycaemia and without weight gain was significantly higher with semaglutide at doses of 0.5 mg and 1 mg (up to 66 % and 74 %, respectively) versus patients treated with sitagliptin (27 %), exenatide ER (29 %), insulin glargine (16%), dulaglutide 0.75 mg (44 %) and dulaglutide 1.5 mg (58 %)
B.BesbesS.ProustM.VincentelliC.AlosB.et al (2020)
Uniqueness: Lipo Lab is known for its ability to target specific areas, giving a more sculpted body shape
While these findings are observational and require confirmation in prospective studies, they highlight the potential of GLP-1 therapies to influence long-term musculoskeletal and inflammatory outcomes in patients with diabetes. For more information: Betul Ibis, MD, can be reached at [email protected].
US$ 24.30
US$ 26.28
